A YORK-BASED medical diagnostic company has achieved a major milestone with the signing of a global distribution agreement.

Abingdon Health, whose manufacturing and head office is at Sand Hutton, has agreed the partnership with Sebia, a major global diagnostic company, for the latter to distribute Seralite® -FLC serum lateral flow immunoassays for the diagnosis and monitoring of multiple myeloma.

Abingdon Health said Seralite® -FLC is the most recent generation of rapid, smart and easy-to-operate test for the quantitative measurement of free kappa and free lambda light chains in blood. Serum-free light chain (sFLC) testing is prescribed to help detect, diagnose and monitor plasma cell disorders such as multiple myeloma, and to monitor the effectiveness of treatments.

Chris Yates, Abingdon Health’s chief executive, said: “ Sebia’s global reach and market leadership in the provision of electrophoresis testing makes it the perfect partner to launch our new product worldwide.”